Cyheptamide is a drug that was formerly used as an anticonvulsant. It is a derivative of diphenylhydantoin, a well-known antiepileptic drug. Cyheptamide was synthesized in the 1950s and was marketed for the treatment of epilepsy. The mechanism of action of cyheptamide is not fully understood but is thought to involve modulation of the activity of voltage-gated sodium channels, which are essential for the generation of action potentials in neurons. Cyheptamide was effective in controlling seizures in some patients but was associated with a number of adverse effects, including drowsiness, dizziness, and liver damage. As a result, its use has declined significantly in recent years. However, it remains of interest to researchers as a potential model compound for the development of new antiepileptic drugs. In 2015, cyheptamide was found to have significant activity against the SARS virus. Further research is needed to determine the exact mechanism of action of cyheptamide against SARS and to assess its potential as a therapeutic agent.'
cyheptamide: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 23603 |
| CHEMBL ID | 1868301 |
| SCHEMBL ID | 667894 |
| MeSH ID | M0043208 |
| Synonym |
|---|
| cyheptamide |
| 5h-dibenzo[a,d]cycloheptene-5-carboxamide, 10,11-dihydro- |
| D03628 |
| 7199-29-3 |
| cyheptamide (usan/inn) |
| cyheptamide [usan:inn] |
| einecs 230-570-8 |
| ciheptamida [inn-spanish] |
| dibenzo(a,d)(1,4)-cycloheptadiene-5-carboxamide |
| dibenzo(a,d)cycloheptadiene-5-carboxamide |
| 5h-dibenzo(a,d)cycloheptene-5-carboxamide, 10,11-dihydro- |
| 10,11-dihydro-5h-dibenzocycloheptene-5-carboxamide |
| bs 7029 |
| 10,11-dihydro-5h-dibenzo(a,d)cycloheptene-5-carboxamide |
| brn 2273660 |
| ici 51426 |
| ay 8682 |
| cyheptamidum [inn-latin] |
| cyheptamine |
| NCGC00166143-01 |
| FT-0665420 |
| cas-7199-29-3 |
| tox21_112337 |
| dtxsid6046551 , |
| dtxcid4026551 |
| CHEMBL1868301 |
| ciheptamida |
| unii-6r22p8k61p |
| cyheptamidum |
| 6r22p8k61p , |
| ay-8682 |
| cyheptamide [mi] |
| cyheptamide [usan] |
| cyheptamide [inn] |
| carbamazepam |
| 10,11-dihydro-5h-dibenzo[a,d]cycloheptene-5-carboxamide |
| SCHEMBL667894 |
| APBVLLORZMAWKI-UHFFFAOYSA-N |
| sr-01000944808 |
| SR-01000944808-1 |
| 10,11-dihydro-5h-dibenz[a,d]cycloheptene-5-carboxamide |
| cyheptamiede form-iii |
| Q27265364 |
| tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaene-2-carboxamide |
| 5h-dibenzo[a,d]cycloheptene-5-carboxamide,10,11-dihydro- |
| tricyclo[9.4.0.0?,?]pentadeca-1(15),3,5,7,11,13-hexaene-2-carboxamide |
| AKOS040745690 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID504749 | qHTS profiling for inhibitors of Plasmodium falciparum proliferation | 2011 | Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043 | Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 4 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (17.31) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||